KCG
LXRX icon

Knight Capital Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Knight Capital Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$28K Buy
+1,833
New +$27.9K ﹤0.01% 3140

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Knight Capital Group's LXRX Position: Q2 2013 in Review

Knight Capital Group opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2013: 1,833 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #3140 among its holdings.

103 funds tracked by Wall St. Rank hold LXRX as of Q2 2013.

  • Knight Capital Group held 1,833 shares of Lexicon Pharmaceuticals worth $28K as of Q2 2013.
  • Lexicon Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3140 holding.
  • 103 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.